Bay Area's TriVascular, Inc. Falls Short Of IPO Target, Raises $78 Million

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TriVascular Technologies, the only Bay Area company going public this week, fell short of its IPO target but raised $78 million in the latest sign of weakness in the market for new stocks. The Santa Rosa company led by CEO Christopher Chavez sold 6.5 million shares at $12, below the expected range of between $13 and $15. It was one of three U.S. companies to miss their marks on Tuesday.

Help employers find you! Check out all the jobs and post your resume.

Back to news